Internal Medicine Department, Amita-Presence Saint Joseph Hospital, Chicago, 2900 N Lakeshore Drive, Chicago, IL 60657, USA.
Internal Medicine Department, Louis A Weiss Memorial Hospital, Chicago, IL, USA.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926853. doi: 10.1177/1753466620926853.
COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection.
新冠疫情已经在全球蔓延，给世界各地的医疗保健系统带来了巨大压力。目前当务之急是寻找针对这种致命病毒的治疗方法。在本研究中，我们根据网上可获得的文献，综述了新冠疫情中常见的经验性治疗方法，重点关注了人类在严重急性呼吸系统综合征冠状病毒（SARS-COV-1）和其他病毒方面的治疗经验。恢复期血液制品是最有希望用于治疗新冠的方法。氯喹或羟氯喹（HCQ）、瑞德西韦和托珠单抗等也是有前途的潜在疗法，但它们仍需在随机临床试验（RCT）中进行测试。洛匹那韦-利托那韦在一项大型 RCT 中并未显示出益处。基于 SARS-COV-1 和中东呼吸综合征（MERS）感染患者的危害提示，不建议在新冠病毒肺炎中使用皮质类固醇，除非用于其他指征。
